Protective effects of montelukast on vancomycin-induced kidney damage

Evaluation of the protective effects of montelukast on vancomycin-induced kidney damage in children

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220519054919N1

Enrollment

Registered

2022-06-18

Start date

2022-05-31

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute renal injury.

Interventions

Intervention 1: Intervention group: Vancomycin is given to both groups at a dose of 40-60 mg based on weight per day. In the intervention group, in addition to receiving vancomycin, the child is given

Eligibility

Sex/Gender

All

Age

2 Years to 18 Years

Inclusion criteria

Inclusion criteria: All children receiving vancomycin over two years of age

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Renal injury due to vancomycin. Timepoint: Patients' creatinine is measured every 48 hours. Method of measurement: Measurement of patients' creatinine.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArezu Javaheripour

Arak University of Medical Sciences

Arezujavaheri.70@gmail.com+98 86 3313 5603

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026